Email this article The third-line therapy for patients with metastatic colorectal cancer: regorafenib or repeated administration of drugs? A review
- Authors: Rykov I.V.1, Chubenko V.A.2
-
Affiliations:
- Saint Petersburg Clinical Hospital
- Saint-Petersburg Clinical Scientific and Practical Center for Special Types of Medical Care (oncology-oriented)
- Issue: Vol 24, No 2 (2022)
- Pages: 204-208
- Section: CLINICAL ONCOLOGY
- URL: https://journal-vniispk.ru/1815-1434/article/view/109345
- DOI: https://doi.org/10.26442/18151434.2022.2.201555
- ID: 109345
Cite item
Full Text
Abstract
To this date, the treatment of metastatic colorectal cancer involves continuous drug therapy, the so-called "continuum of care" approach in order to control of tumor growth and try to increase life expectancy for patients. The characteristic is the limited availability and insufficient number of third- and subsequent-line therapy. The main options for the treatment of resistant forms of metastatic colorectal cancer in real practice are the alternation of chemotherapy regimens, targeted drugs and the application of regorafenib. The choice of the treatment tactics is influenced by the patient's condition, the previous treatment and the efficacy, the molecular status of the tumor. The correct sequence of use of such approaches is currently not clearly defined and is the subject of many discussions and retrospective studies. The article discusses the main trends in the application of targeted antiangiogenic therapy for this category of patients.
Full Text
##article.viewOnOriginalSite##About the authors
Ivan V. Rykov
Saint Petersburg Clinical Hospital
Author for correspondence.
Email: rykov.ivan@gmail.com
ORCID iD: 0000-0002-8250-8144
Cand. Sci. (Med.)
Russian Federation, Saint PetersburgViacheslav A. Chubenko
Saint-Petersburg Clinical Scientific and Practical Center for Special Types of Medical Care (oncology-oriented)
Email: vchubenko@me.com
ORCID iD: 0000-0001-6644-6687
Cand. Sci. (Med.)
Russian Federation, Saint PetersburgReferences
- World Health Organization. GLOBOCAN 2020 (IARC). Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf/ Accessed: 14.02.2022.
- Трякин А.А. Место регорафениба в лечении метастатического колоректального рака. Современная Онкология. 2016;18(2):52-6 [Tryakin AA. The role of regorafenib in the treatment of metastatic colorectal cancer. Journal of Modern Oncology. 2016;18(2):52-6 (in Russian)].
- Федянин М.Ю., Трякин А.А., Тюляндин С.А. Локализация первичной опухоли толстой кишки: есть ли принципиальные отличия? Онкологическая колопроктология. 2017;7(3):35-48 [Fedyanin MYu, Tryakin AA, Tjulandin SA. Localization of the primary tumor of the colon: аre there essential differences? Colorectal Oncology. 2017;7(3):35-48]. doi: 10.17650/2220-3478-2017-7-3-35-48
- Федянин М.Ю., Ачкасов С.И., Болотина Л.В., и др. Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения. Злокачественные опухоли. 2021;11(3s2-1):330-72 [Fedianin MIu, Achkasov SI, Bolotina LV, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu raka obodochnoi kishki i rektosigmoidnogo soedineniia. Zlokachestvennye opukholi. 2021;11(3s2-1):330-72 (in Russian)]. doi: 10.18027/2224-5057-2020-10-3s2-22
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Updates in Version 1.2022 of the NCCN Guidelines for Colon Cancer from Version 3.2021.
- Hanovich E, Asmis T, Ong M, Stewart D. Rechallenge Strategy in Cancer Therapy. Oncology. 2020;98(10):669-79. doi: 10.1159/000507816
- Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27(34):5727-33. doi: 10.1200/JCO.2009.23.4344
- Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer with Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5(3):343-50. doi: 10.1001/jamaoncol.2018.5080
- Masuishi T, Tsuji A, Kotaka M, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br J Cancer. 2020;123(10):1490-5. doi: 10.1038/s41416-020-01042-w
- Suenaga M, Mizunuma N, Matsusaka S, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther. 2015;9:3099-108. doi: 10.2147/DDDT.S85567
- Yang Q, Huang Y, Jiang Z, et al. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer. Onco Targets Ther. 2018;11:2467-73. doi: 10.2147/OTT.S154220
- Fernandes GDS, Braghiroli MI, Artioli M, et al. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. J Gastrointest Cancer. 2018;49(4):470-5. doi: 10.1007/s12029-017-0001-3
- Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol. 2013;36(1):49-52. doi: 10.1097/COC.0b013e31823fe40e
- Sgouros J, Aravantinos G, Dragasis S, et al. Reintroduction of irinotecan and oxaliplatin as a combination (IROX regimen) in heavily pretreated colorectal cancer patients – A single-center experience. FCO. 2013;4(3):13-8.
- Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7
- Köstek O, Hacıoğlu MB, Sakin A, et al. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Cancer Chemother Pharmacol. 2019;83(1):115-22. doi: 10.1007/s00280-018-3713-6
Supplementary files
Supplementary Files
Action
1.
JATS XML
2.
Fig. 1. Kaplan–Meier estimates of progression-free survival (a) and overall survival (b) according to RAS and BRAF circulating tumor DNA (ctDNA) status.
Download (155KB)
3.
Fig. 2. Progression-free survival (a) and overall survival (b) by cetuximab-free interval.
Download (112KB)
4.
Fig. 3. OS after the beginning of the first-line therapy (RE-OPEN study). The median OS is 300 days, the median PFS is 98 days.
Download (57KB)
5.
Fig. 4. Response to treatment of patients using oxaliplatin reintroduction (RE-OPEN study). Complete response – 0%, partial response – 6.1%, stabilization – 33.3%, progression – 54.5%.
Download (47KB)
6.
Fig. 5. OS of patient in the CONCUR and CORRECT trials.
Download (126KB)
